Watch the interview with Idogen's interim CEO Christina Herder below.
In connection with the BioStock Investor Meeting in Stockholm, BioStock took the opportunity to interview Christina Herder, Idogen's newly appointed interim CEO. In addition to talking about the upcoming phase I/IIa study with the lead candidate IDO8, Herder also discussed the potential of the company's other two projects, IDO AID and IDO T.